


Journal Pre-proof



Impact of a High-Risk, Ambulatory COVID-19 Remote Patient Monitoring Program on Utilization, Cost, and Mortality

Tufia C. Haddad, MD, Jordan D. Coffey, MBA, MHA, MA, Yihong Deng, PhD, Amy E. Glasgow, MHA, Laura A. Christopherson, MBA, Lindsey R. Sangaralingham, MPH, Sarah J. Bell, MSN, MHA, RN, Vishal P. Shah, MD, Joshua C. Pritchett, MD, Robert Orenstein, DO, Leigh L. Speicher, MD, Michael J. Maniaci, MD, Ravindra Ganesh, MBBS, MD, Bijan J. Borah, PhD

PII: S0025-6196(22)00510-9

DOI: <https://doi.org/10.1016/j.mayocp.2022.08.015>

Reference: JMCP 3933

To appear in: *Mayo Clinic Proceedings*

Received Date: 5 August 2022

Accepted Date: 30 August 2022

Please cite this article as: Haddad TC, Coffey JD, Deng Y, Glasgow AE, Christopherson LA, Sangaralingham LR, Bell SJ, Shah VP, Pritchett JC, Orenstein R, Speicher LL, Maniaci MJ, Ganesh R, Borah BJ, Impact of a High-Risk, Ambulatory COVID-19 Remote Patient Monitoring Program on Utilization, Cost, and Mortality, *Mayo Clinic Proceedings* (2022), doi: <https://doi.org/10.1016/j.mayocp.2022.08.015>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2022 Mayo Foundation for Medical Education and Research

Impact of a High-Risk, Ambulatory COVID-19 Remote Patient Monitoring Program on Utilization, Cost, and Mortality

Tufia C. Haddad, MD*^{1,2}; Jordan D. Coffey, MBA, MHA, MA¹; Yihong Deng, PhD³; Amy E. Glasgow, MHA³; Laura A. Christopherson, MBA¹; Lindsey R. Sangaralingham, MPH³; Sarah J. Bell, MSN, MHA, RN^{1,4}; Vishal P. Shah, MD^{3,5}; Joshua C. Pritchett, MD^{2,3}; Robert Orenstein, DO⁶; Leigh L. Speicher, MD⁷; Michael J. Maniaci, MD^{1,7}; Ravindra Ganesh, MBBS, MD⁵; Bijan J. Borah, PhD^{3,8}

Author Affiliations:

1 Center for Digital Health, Mayo Clinic, Rochester, MN

2 Department of Oncology, Mayo Clinic, Rochester, MN

3 Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN

4 Department of Nursing, Mayo Clinic, Rochester, MN

5 Department of Medicine, Mayo Clinic, Rochester, MN

6 Department of Medicine, Mayo Clinic, Scottsdale, AZ

7 Department of Medicine, Mayo Clinic, Jacksonville, FL

8 Division of Health Care Delivery Science, Mayo Clinic, Rochester, MN

***Corresponding Author:**

Tufia Haddad, MD

200 First Street S.W.

Rochester, MN, 55905

Phone: 507-284-2511

Fax: 507-284-1803

Email: haddad.tufia@mayo.edu

ORCID: 0000-0001-8226-3581

Funding/Support: This study was in part made possible by funding from the Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery. The funders had no role in the study design, conduct, and preparation of the manuscript. The Mayo Clinic Remote Patient Monitoring program is an enterprise shared service supported by the Mayo Clinic practice. There were no funding sources external to Mayo Clinic associated with this research study.

Conflict of Interest Disclosures:

TCH – Research grant funding from Takeda Oncology to Mayo Clinic to conduct a clinical trial unrelated to the research presented in this manuscript.

JDC – No COI to report.

YD – No COI to report.

AEG – No COI to report.

LAC – No COI to report.

LRS - No COI to report.

SB - No COI to report.

VPS – No COI to report.

JCP – No COI to report.

RO – No COI to report.

LLS – No COI to report.

MJM – No COI to report.

RG – No COI to report.

BJB - Bijan J. Borah declares being a consultant to Exact Sciences and Boehringer Ingelheim in the last three years on topics NOT related to the content of the manuscript.

ABSTRACT

Objective: To evaluate care utilization, cost, and mortality among high-risk patients enrolled in a COVID-19 Remote Patient Monitoring (RPM) program.

Methods: This retrospective analysis included patients diagnosed with COVID-19 at risk for severe disease who enrolled in the RPM program between March 2020 - October 2021. The program included in-home technology for symptom and physiologic data monitoring with centralized care management. Propensity score matching established matched cohorts of RPM-engaged (defined as ≥ 1 RPM technology interactions) and non-engaged patients using a logistic regression model of 59 baseline characteristics. Billing codes and the electronic death certificate system were utilized for data abstraction from the EHR and reporting of care utilization and mortality endpoints.

Results: Among 5,796 RPM-enrolled patients, 80.0% engaged with the technology. Following matching, 1,128 pairs of RPM engaged and non-engaged patients comprised the analysis cohorts. Mean patient age was 63.3 years, 50.9% of patients were female sex, and 81.9% were non-Hispanic, white. RPM-engaged patients experienced significantly lower rates of 30-day, all-cause hospitalization (13.7% vs 18.0%, $P=.01$), prolonged hospitalization (3.5% vs 6.7%, $P=.001$), ICU admission (2.3% vs. 4.2%, $P=.01$), and mortality [0.5% vs. 1.7%, OR 0.31 (0.12, 0.78), $P=.01$], as well as cost of care (\$2,306.33 USD vs \$3,565.97 USD, $P=0.04$), than those enrolled in RPM but non-engaged.

Conclusions: High-risk, COVID-19 patients enrolled and engaged in an RPM program experienced lower rates of hospitalization, ICU admission, mortality, and cost than those enrolled and non-engaged. These findings translate to improved hospital bed access and patient outcomes.

Journal Pre-proof

ABBREVIATIONS

COVID-19: Coronavirus Disease 2019

RPM: Remote Patient Monitoring

ED: Emergency Department

ICU: Intensive Care Unit

EHR: Electronic health record

SMD: Standardized mean differences

USD: U.S. Dollars

Journal Pre-proof

INTRODUCTION

In response to the COVID-19 pandemic, many health care organizations implemented remote patient monitoring (RPM) programs to support patients with suspected or confirmed COVID-19 infections, following a confirmed diagnosis or upon hospital discharge for the disease¹⁻⁹. These programs were enabled by various technologies, including automated short message service (SMS)⁸, mobile applications³, or preconfigured devices¹ with questionnaires for symptom tracking; peripheral medical devices or wearables for monitoring physiologic data; and/or telephone and video telehealth visits⁶⁻⁷. Most programs provided centralized clinical support, integration of the patient-generated health data with the electronic health record (EHR), and were associated with high patient satisfaction^{4-5, 8, 10}.

At Mayo Clinic, our team developed a COVID-19 RPM care model to support ambulatory patients with COVID-19 through the acute phase of illness, as well as those discharging from a complex COVID-19 hospitalization^{1, 11-12}. For the high-intensity RPM program, all patients were required to be at risk for severe COVID-19 disease¹³, and the in-home technology package was provided at no cost to patients. The technology-enabled monitoring was comprised of at least twice daily patient-reported symptom assessments and physiologic data obtained from connected devices. A centralized team of registered nurses (RNs) responded to alerts and escalated care as needed to COVID-19 care team providers. This high-intensity program was designed to meet Centers for Medicare and Medicaid Services criteria (CMS) requirements as a billable RPM program¹⁴ which, in the absence of a universally accepted standard, represents the highest standard for an RPM program definition.

We previously reported the development and implementation of this multi-site, multi-regional, interdisciplinary COVID-19 RPM program¹ which included a descriptive analysis of a diverse cohort of 7,074 patients served by the program (including both low and high-intensity monitoring) across 41 U.S. states with an age range of 17-101 years and 27.5% racial/ethnic minority representation. Among patients engaged in high-intensity monitoring, the RPM technology engagement rate was 78.4%. Emergency department visit, hospital admission, and mortality rates within 30 days of RPM enrollment were 11.4%, 9.4%, and 0.6% respectively.

Herein we report results of a retrospective, matched cohort analysis of the high-intensity COVID-19 RPM program. The primary objective of this study was to evaluate care utilization among all eligible and enrolled in the RPM program, comparing those who did or did not engage with the technology. Secondary objectives were to evaluate cost and mortality in these cohorts. We hypothesized that identification of adverse health trends by the RPM technology and centralized care team would be associated with a reduction in hospital utilization.

METHODS

Patients

Patients were eligible for the RPM program if they had a positive SARS-CoV-2 test at a Mayo Clinic location and one or more risk factors for severe COVID-19 illness as defined by the Centers for Disease Control (CDC) and expert consensus¹³. Patients were required to reside within the United States; however, those living in a skilled nursing facility were not eligible. Patients were not required to speak English language or have a primary care provider, and they could participate regardless of underlying diseases and conditions.

Setting

Mayo Clinic is a nonprofit, specialty group practice with integrated research, education, and clinical practice activities. Patients were included in this study if they were diagnosed with COVID-19 at a Mayo Clinic hospital or ambulatory clinic within the Midwest tertiary campus (Rochester, Minnesota) or the affiliated Mayo Clinic Health System (MCHS), comprised of over 70 Midwest, community-based hospitals and clinics in Southern Minnesota, Northern Iowa, and Western Wisconsin.

RPM Intervention

At the outset of the COVID-19 pandemic, Mayo Clinic adapted its chronic disease and post-surgical/procedural RPM program to meet the unique needs of patients with acute COVID-19. Patients who enrolled in the high-intensity COVID-19 RPM program received a technology package comprised of a cellular-enabled tablet, preconnected, Bluetooth-enabled, medical grade devices (blood pressure cuff, pulse oximeter, and scale), and a thermometer for self-reported temperature. Vital sign measurements and symptom assessment questions were completed 2-4 times daily (four times for those immunosuppressed or receiving cancer-directed therapy). All patient generated health data were integrated into the EHR. Alerts were triggered based on pre-determined parameters. A centralized team of RNs responded to technology-generated alerts and utilized standardized care pathways for clinical assessments and patient management, including escalation to a COVID-19 care team of General Internal Medicine and Infectious Disease physicians and advanced practice providers. Clinical support was provided 24 hours per day, seven days a week, including weekends and holidays. Program

eligibility criteria, technology solution, and clinical operational model have been previously described¹.

Study Design and Endpoints

A retrospective cohort analysis was conducted evaluating patients enrolled in the COVID-19 RPM program. Study endpoints included all-cause healthcare utilization, total cost of care, and mortality outcomes within 30 days of the COVID-19 RPM program enrollment (index) date, regardless of attribution to COVID-19. Data were abstracted from the EHR (Epic Systems, version May 2020), using validated billing reports for utilization endpoints and electronic death certificate data for mortality.

All-cause costs during the 30-day follow-up were abstracted from the Mayo Clinic Cost Data Warehouse, which has been previously described¹⁵. Charges for hospital-based services were costed using Medicare cost-to-charge ratios, while the professional services were costed using the Medicare reimbursement rates for the corresponding CPT/HCPCS codes. The total cost was defined as the sum of both these costs and reported in U.S. Dollars (USD).

Analysis Plan

To control for possible confounding, a propensity score-matched cohort was constructed to compare patient outcomes among those enrolled in the RPM program and “engaged,” as defined by one or more sets of vitals/symptoms submitted through the supplied technology, with those “non-engaged,” who enrolled but did not engage with the RPM technology.

Specifically, one-to-one nearest-neighbor caliper matching was used to match engaged and non-engaged patients using a caliper equal to 0.2 of the standard deviation of the logit of the

propensity score¹⁶. The propensity score was estimated using a logistic regression model based on 59 baseline characteristics including age, sex, race and other demographics, comorbidities, prior healthcare utilization, primary care empanelment at Mayo Clinic, EHR portal account access (web or mobile-based), and COVID-19 index date month/year. Standardized mean differences (SMD) were used to assess the balance of covariates after matching, with an SMD less than or equal to 0.1 indicating covariate balance. Baseline Elixhauser comorbidity scores, COVID-19 risk factors, and utilization were calculated using ICD-10 diagnosis codes within one year prior to index date. Logistic regression and t-test were used to compare engaged with non-engaged patients for binary and continuous outcomes, respectively.

Two subgroup analyses were performed for those patients who enrolled in the RPM program: (1) at the time of hospital discharge (following acute illness), and (2) after diagnosis in the outpatient setting (during acute illness).

Propensity score modeling and analyses were performed utilizing Stata 16.1 (StataCorp, College Station, Texas). This study was approved by the Mayo Clinic Institutional Review Board (#18-009605).

RESULTS

Between March 16, 2020, and October 18, 2021, 9,679 high-risk patients enrolled in the COVID-19 RPM program. Among these patients, 5,796 were evaluable and comprised the analysis cohort (Figure 1). Reasons for exclusion included lack of authorization for retrospective research, assignment to low-intensity monitoring, sex and risk score missing (required for matching). Patients were also excluded if they died or were hospitalized within 1 day of

enrollment, as the RPM technology package is typically delivered to the patient's home the day after enrollment. Additionally, those managed in the Mayo Clinic Southwest (Scottsdale, AZ) and Southeast (Jacksonville, FL) regions (n=1,950) were excluded from the analysis given most patients only receive specialty care, but not routine care (including emergency department visits and hospitalizations), at Mayo Clinic, and to mitigate effect of regional variability on comparative outcomes assessment.

Of the evaluable patients, 1,162 (20.0%) did not engage with the technology. Prior to matching, non-engaged patients were generally older, with more comorbidities, or diagnosed with COVID-19 in the hospital (Table 1); however, sex, race, ethnicity, and primary language were similar between engaged and non-engaged cohorts.

After matching (Table 2), when compared with the non-engaged patients, those engaged in the RPM program experienced a significantly lower rate of one or more hospitalization (13.7% vs 18.0%, $P=0.01$), prolonged hospitalization 7 or more days (3.5% vs 6.7%, $P=0.001$), and ICU admission (2.3% vs 4.2%, $P=0.01$), as well as a significantly lower average hospital length of stay (6.7 vs 8.2 days, $P=0.04$). Total ICU days were markedly less for those engaged relative to those who were non-engaged (119 vs 313 days, $P=.21$); however, the difference was not statistically significant. Rates of one or more emergency department (ED) visits were similar among groups; however, those engaged were more likely to experience two or more ED visits (4.3% vs 2.4%, $P=0.01$) than those non-engaged.

Those who were engaged in RPM experienced a significantly lower overall 30-day cost of care than those non-engaged (\$2,306.33 USD vs \$3,565.97 USD, $P=0.04$). The average cost saving among engaged RPM patients was \$1,259 per patient during the 30-day follow-up period.

All-cause, 30-day mortality rates were significantly lower for those who engaged in the RPM program than those non-engaged [0.5% vs. 1.7%, OR 0.31 (0.12, 0.78), $P=0.01$].

In a subgroup analysis of patients diagnosed with COVID-19 while hospitalized and RPM-enrolled upon discharge to home (Table 3), the rates of subsequent ED visits and re-hospitalizations were similar between groups. However, the rate of prolonged hospitalization and mean length of stay were significantly lower for those engaged than those non-engaged.

A separate subgroup analysis of patients with COVID-19 diagnosed and RPM-enrolled in the ambulatory setting (Table 4) revealed that when compared with non-engaged patients, engaged patients had higher rates of 2 or more ED visits, but lower rates of hospital admission, prolonged hospitalization, ICU admission, and mortality. These outcome trends were similar to those for the overall cohort.

DISCUSSION

This study suggests that patients with COVID-19 at risk for severe disease who enrolled and engaged in the RPM program experienced significantly lower rates of 30-day, all-cause hospital utilization, total cost of care, and mortality when compared with those who were non-engaged, especially when diagnosed and managed in the ambulatory setting through the acute phase of illness. We postulate the RPM program facilitated detection of adverse health trends and

enabled early supportive care interventions, which in turn favorably altered the COVID-19 disease trajectory. As hospital bed and ICU capacity have been severely strained during the pandemic¹⁷, these findings build upon our prior observations^{1, 11} and those of others¹⁸, and they provide a potential strategy to improve hospital access.

Furthermore, as racial/ethnic minority populations were as likely to engage in the RPM program as non-Hispanic white patients, it is feasible that RPM programs could help improve outcomes in this cohort disproportionately impacted by COVID-19¹⁹. This was an important and unexpected observation given RPM program participation was declined by several racial/ethnic minority, migrant workers at a meatpacking plant in the early days of the pandemic²⁰.

Among those diagnosed while hospitalized during the acute phase of COVID-19, we expected the RPM program to enable earlier discharge, as demonstrated by others^{3, 5}. Our findings suggest that post-discharge RPM engagement may not reduce subsequent ED visits and re-admissions during the recovery phase; however, it was associated with a reduced mean hospital length of stay, which still conveys an improvement in bed capacity.

ED visit rates were similar between groups; however, the multiple ED visit rate for those engaged with RPM was higher than for those non-engaged. These findings were anticipated as deteriorating patients were sent to the ED per established workflows. Future program iterations incorporating tele-emergency medicine and community paramedics are being explored to enhance in-home diagnostics, triage, and supportive care treatment interventions, such as IV fluid administration and initiation of supplemental oxygen.

Compared to non-engaged patients, the total cost savings for 1,128 matched patients that were engaged in the COVID-19 RPM program was approximately \$1.4 million. Thus, a well-engaged RPM program not only results in lower hospital utilization and better patient outcomes, but it could potentially yield substantial healthcare cost savings for patients and health systems.

There are several strengths of this COVID-19 RPM program analysis: (1) large cohort size (1,128 matched pairs), (2) matching on 59 confounding variables, (3) inclusive representation of elderly, rural, and underrepresented minority populations, and (4) RPM program technology and clinical operational model that qualifies as a billable service by CMS criteria¹⁴. Importantly, this is among the first known reports to demonstrate improved care utilization rates among high-risk patients diagnosed with COVID-19 when managed and engaged in an ambulatory RPM program. Additionally, program engagement was associated with improved mortality and total cost of care.

However, results must be interpreted within the limitations of retrospective study design. We did not compare outcomes of those enrolled to the RPM program with those not enrolled under the “intention-to-treat” principle, as we could not identify a comparable high-risk control group managed without RPM. This finding was not entirely surprising, as our COVID-19 care team physicians depended on the RPM program for care delivery at scale, especially to support ambulatory management of patients with COVID-19 at risk for severe disease. For this reason, as well, they refused a prospective randomized trial of RPM versus usual care for COVID-19 management. Therefore, we focused on eligible and enrolled to the RPM program using an “as-treated” analysis. The authors recognize that patients who do not engage with the RPM

technology may have a general predisposition to not engage with healthcare and acknowledge that participation bias may exist with this analysis. That said, some patients were non-engaged simply by lack of timely receipt of the technology package, especially during surges which strained the supply chain. Finally, the propensity score matching adjusted only for the observed patient characteristics, but not the unobserved ones. The latter may include subjective factors that are associated with patient engagement; however, the cohorts were matched by portal access, an indicator of cellular or broadband telehealth access and indirect measure of digital literacy. Inability to adjust for unobserved or unmeasured variables is a well-acknowledged limitation of any retrospective study, including ours. Such unobserved confounding can be eliminated only through a prospective randomized controlled trial, which was not feasible at our institution during the COVID-19 pandemic.

Our findings on well-engaged RPM have potential policy and reimbursement implications for extending this acute care delivery model beyond the pandemic while additional prospective, confirmatory studies are performed. Further mixed-methods research is also needed to understand why enrolled patients do not engage with the technology and to evaluate the cost effectiveness of the program.

ACKNOWLEDGMENTS**Author contributions**

Tufia Haddad and Bijan Borah had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Tufia Haddad, Jordan Coffey, and Lindsey Sangaralingham with input from Bijan Borah, Ravindra Ganesh, and Joshua Pritchett.

Acquisition, analysis, or interpretation of data: Led by Lindsey Sangaralingham and Amy Glasgow with input from Jordan Coffey, Tufia Haddad, Yihong Deng, and Bijan Borah. Ravindra Ganesh, Robert Orenstein, and Leigh Speicher facilitated RPM care team oversight and direct patient-related data acquisition.

Drafting of manuscript: Initial draft of the manuscript was prepared by Tufia Haddad, Jordan Coffey, Laura Christopherson, Vishal Shah, Sarah Bell, Yihong Deng, Michael Maniaci, and Bijan Borah.

Critical revisions of manuscript for important intellectual content: All authors provided critical revisions as key stakeholders in the RPM program and analysis contributing to the overall intellectual content. All endorsed the final draft.

Statistical analysis: Yihong Deng and Lindsey Sangaralingham.

Obtained funding: Not applicable.

Administrative, technical, or material support: Tufia Haddad, Jordan Coffey, Sarah Bell, Laura Christopherson, and Lindsey Sangaralingham.

Supervision: Tufia Haddad and Bijan Borah.

REFERENCES

1. Coffey, J.D., L.A. Christopherson, A.E. Glasgow, et al. Implementation of a multisite, interdisciplinary remote patient monitoring program for ambulatory management of patients with COVID-19, 2021. *NPJ Digit Med.* 2021; 4(1): 123. DOI: 10.1038/s41746-021-00490-9
2. Mantena, S. and S. Keshavjee. Strengthening healthcare delivery with remote patient monitoring in the time of COVID-19, 2021. *BMJ Health Care Inform.* 2021; 28(1). DOI: 10.1136/bmjhci-2020-100302
3. Gordon, W.J., D. Henderson, A. DeSharone, et al. Remote Patient Monitoring Program for Hospital Discharged COVID-19 Patients, 2020. *Appl Clin Inform.* 2020; 11(5): 792-801. DOI: 10.1055/s-0040-1721039
4. Kodama, R., S. Arora, S. Anand, et al. Reengineering the Discharge Transition Process of COVID-19 Patients Using Telemedicine, Remote Patient Monitoring, and Around-the-Clock Remote Patient Monitoring from the Emergency Department and Inpatient Units, 2021. *Telemed J E Health.* 2021; 27(10): 1188-1193. DOI: 10.1089/tmj.2020.0459
5. Grutters, L.A., K.I. Majoor, E.S.K. Mattern, et al. Home telemonitoring makes early hospital discharge of COVID-19 patients possible, 2020. *J Am Med Inform Assoc.* 2020; 27(11): 1825-1827. DOI: 10.1093/jamia/ocaa168
6. Bell, L.C., C. Norris-Grey, A. Luintel, et al. Implementation and evaluation of a COVID-19 rapid follow-up service for patients discharged from the emergency department, 2021. *Clin Med (Lond).* 2021; 21(1): e57-e62. DOI: 10.7861/clinmed.2020-0816

7. Medina, M., C. Babiuch, M. Card, et al. Home monitoring for COVID-19, 2020. *Cleve Clin J Med*. 2020. DOI: 10.3949/ccjm.87a.ccc028
8. Morgan AU, Balachandran M, Do D, et al. Remote Monitoring of Patients with Covid-19: Design, implementation, and outcomes of the first 3,000 patients in COVID Watch. *NEJM Catalyst, Innovations in Care Delivery*. Published July 21, 2020. Available from: <https://catalyst.nejm.org/doi/full/10.1056/CAT.20.0342>. Accessed January 27, 2022
9. Annis, T., S. Pleasants, G. Hultman, et al. Rapid implementation of a COVID-19 remote patient monitoring program, 2020. *J Am Med Inform Assoc*. 2020; 27(8): 1326-1330. DOI: 10.1093/jamia/ocaa097
10. Daly, B., T.S. Lauria, J.C. Holland, et al. Oncology Patients' Perspectives on Remote Patient Monitoring for COVID-19, 2021. *JCO Oncol Pract*. 2021; 17(9): e1278-e1285. DOI: 10.1200/OP.21.00269
11. Pritchett, J.C., B.J. Borah, A.P. Desai, et al. Association of a Remote Patient Monitoring (RPM) Program With Reduced Hospitalizations in Cancer Patients With COVID-19, 2021. *JCO Oncol Pract*. 2021; 17(9): e1293-e1302. DOI: 10.1200/OP.21.00307
12. Haddad, T.C., R.N. Blegen, J.E. Prigge, et al. A Scalable Framework for Telehealth: The Mayo Clinic Center for Connected Care Response to the COVID-19 Pandemic, 2021. *Telemed Rep*. 2021; 2(1): 78-87. DOI: 10.1089/tmr.2020.0032
13. U.S. Centers for Disease Control and Prevention. Evidence for Conditions that Increase Risk of Severe Illness. June 15, 2022. <https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/underlying-evidence-table.html>. Accessed July 23, 2022.,

14. U.S. Centers for Medicare & Medicaid Services. Final Policy, Payment, and Quality Provisions Changes to the Medicare Physician Fee Schedule for Calendar Year 2021. December 1, 2020. <https://www.cms.gov/newsroom/fact-sheets/final-policy-payment-and-quality-provisions-changes-medicare-physician-fee-schedule-calendar-year-1>. Accessed February 10, 2022.
15. Visscher, S.L., J.M. Naessens, B.P. Yawn, et al. Developing a standardized healthcare cost data warehouse, 2017. *BMC Health Serv Res.* 2017; 17(1): 396. DOI: 10.1186/s12913-017-2327-8
16. Austin, P.C. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies, 2011. *Pharm Stat.* 2011; 10(2): 150-61. DOI: 10.1002/pst.433
17. Rosenbaum, L. The Untold Toll - The Pandemic's Effects on Patients without Covid-19, 2020. *N Engl J Med.* 2020; 382(24): 2368-2371. DOI: 10.1056/NEJMms2009984
18. Delgado, M.K., A.U. Morgan, D.A. Asch, et al. Comparative Effectiveness of an Automated Text Messaging Service for Monitoring COVID-19 at Home, 2022. *Ann Intern Med.* 2022; 175(2): 179-190. DOI: 10.7326/M21-2019
19. Gross, C.P., U.R. Essien, S. Pasha, et al. Racial and Ethnic Disparities in Population-Level Covid-19 Mortality, 2020. *J Gen Intern Med.* 2020; 35(10): 3097-3099. DOI: 10.1007/s11606-020-06081-w
20. Pritchett, J.C. and T.C. Haddad. Avoiding the "Faux Equalizer", 2021. *Mayo Clin Proc.* 2021; 96(12): 2963-2965. DOI: 10.1016/j.mayocp.2021.08.010

21. Nanda S, Chacin Suarez AS, Toussaint L, et al. Body mass index, multi-morbidity, and COVID-19 risk factors as predictors of severe COVID-19 outcomes. *J Prim Care Community Health*. 2021 Jan-Dec;12. DOI: 10.1177/21501327211018559.
22. Ganesh R, Philpot LM, Bierle DM, et al. Real-world clinical outcomes of bamlanivimab and casirivimab-imdevimab among high-risk patients with mild to moderate coronavirus disease 2019. *J Infect Dis*. 2021 Oct;224(8):1278-1286. DOI: 10.1093/infdis/jiab377

Journal Pre-proof

Figure 1. Flow diagram for patients enrolled in the COVID-19 RPM program and evaluable for the analysis

Journal Pre-proof

Table 1. Patient characteristics

Characteristic ^a	Pre-Matched Population			Matched Population		
	Non-Engaged	Engaged	SMD	Non-Engaged	Engaged	SMD
	(n= 1162)	(n= 4634)		(n= 1128)	(n= 1128)	
Age, years						
Mean (SD)	62.6 (18.4)	57.1 (17.7)	0.31	62.3 (18.4)	64.3 (17.5)	0.10
Median	66.0	59.0		66.0	68.0	
Age distribution						
18-49	278 (23.9%)	1521 (32.8%)	0.20	277 (24.5%)	230 (20.4%)	0.10
50-74	488 (42.0%)	2242 (48.4%)	0.13	476 (42.2%)	495 (43.8%)	0.03
74+	396 (34.1%)	871 (18.8%)	0.35	375 (33.2%)	403 (35.7%)	0.05
Sex						
Female	592 (50.9%)	2443 (52.7%)	0.04	569 (50.4%)	580 (51.4%)	0.02
Male	570 (49.1%)	2191 (47.3%)	0.04	559 (49.6%)	548 (48.6%)	0.02
Married						
	638 (54.9%)	2925 (63.1%)	0.17	629 (55.8%)	607 (53.8%)	0.04
Race/Ethnicity						
White, Non-Hispanic (NH)	941 (81.0%)	3638 (78.5%)	0.07	914 (81.0%)	933 (82.7%)	0.04
Hispanic (all races)	109 (9.4%)	530 (11.4%)	0.07	108 (9.6%)	92 (8.2%)	0.05
Black, NH	38 (3.3%)	176 (3.8%)	0.03	36 (3.2%)	39 (3.5%)	0.02
Asian, NH	13 (1.1%)	99 (2.1%)	0.08	13 (1.2%)	9 (0.8%)	0.04
All other, NH	28 (2.4%)	86 (1.9%)	0.04	26 (2.3%)	25 (2.2%)	0.01
Unknown/Missing	33 (2.8%)	105 (2.3%)	0.04	31 (2.7%)	30 (2.7%)	0.01
Primary Language						
English	1029 (88.6%)	4036 (87.1%)	0.05	997 (88.4%)	1013 (89.8%)	0.05

Spanish	90 (7.7%)	411 (8.9%)	0.04	90 (8.0%)	80 (7.1%)	0.03
Other	38 (3.3%)	184 (3.9%)	0.03	37 (3.3%)	32 (2.9%)	0.02
Missing	5 (0.4%)	3 (0.1%)	0.07	4 (0.4%)	3 (0.3%)	0.02
Paneled to Primary Care	769 (66.2%)	3266 (70.5%)	0.09	753 (66.8%)	770 (68.3%)	0.03
Portal Account^c	793 (68.2%)	3768 (81.3%)	0.31	789 (69.9%)	746 (66.1%)	0.08
Diagnosed in Hospital	255 (21.9%)	679 (14.7%)	0.19	240 (21.3%)	254 (22.5%)	0.03
ED Visits^b	196 (16.9%)	650 (14.0%)	0.08	188 (16.7%)	197 (17.5%)	0.02
Office Visits^b	667 (57.4%)	2826 (61.0%)	0.07	651 (57.7%)	652 (57.8%)	0.00
Hospitalizations^b	264 (22.7%)	798 (17.2%)	0.14	251 (22.3%)	265 (23.5%)	0.03
COVID-19 Risk Factors per						
Patient (Sum)²¹						
Mean (SD)	3.5 (2.2)	3.0 (2.1)	0.17	3.5 (2.2)	3.7 (2.2)	0.09
Median	4.0	3.0		3.0	4.0	
Q1, Q3	2.0, 5.0	1.0, 4.0		2.0, 5.0	2.0, 5.0	
Monoclonal Allocation						
Screening Score²²						
Mean (SD)	4.4 (3.1)	3.8 (2.9)	0.19	4.3 (3.1)	4.5 (2.9)	0.06
Median	4.0	3.0		4.0	5.0	
Q1, Q3	2.0, 7.0	1.0, 6.0		2.0, 7.0	2.0, 7.0	
Elixhauser Score						
Mean (SD)	3.1 (3.2)	2.6 (2.8)	0.17	3.0 (3.2)	3.3 (3.2)	0.07
Median	2.0	2.0		2.0	2.5	
Q1, Q3	0.0, 5.0	0.0, 4.0		0.0, 5.0	0.0, 5.0	
Risk factors for severe						
COVID-19 illness						

Cancer patient	150 (12.9%)	664 (14.3%)	0.04	149 (13.2%)	154 (13.7%)	0.01
Congestive heart failure	214 (18.4%)	569 (12.3%)	0.17	206 (18.2%)	231 (20.5%)	0.06
Chronic lung disease	276 (23.8%)	970 (20.9%)	0.07	267 (23.7%)	277 (24.6%)	0.02
Coronary artery disease	287 (24.7%)	845 (18.2%)	0.16	279 (24.7%)	294 (26.1%)	0.03
Immune compromised	147 (12.7%)	812 (17.5%)	0.13	146 (12.9%)	130 (11.5%)	0.04
End-Stage Renal Disease	248 (21.3%)	703 (15.2%)	0.16	239 (21.2%)	258 (22.9%)	0.04
Arrhythmia	336 (28.9%)	976 (21.1%)	0.18	323 (28.6%)	354 (31.4%)	0.06
Depression	157 (13.5%)	597 (12.9%)	0.02	151 (13.4%)	169 (15.0%)	0.05
Diabetes with chronic complications	231 (19.9%)	777 (16.8%)	0.08	223 (19.8%)	237 (21.0%)	0.03
Diabetes without chronic complications	203 (17.5%)	812 (17.5%)	0.00	197 (17.5%)	201 (17.8%)	0.01
Fluid electrolyte disorder	176 (15.1%)	480 (10.4%)	0.14	166 (14.7%)	190 (16.8%)	0.06
Hypertension, complicated	260 (22.4%)	727 (15.7%)	0.17	251 (22.3%)	274 (24.3%)	0.05
Hypertension, uncomplicated	334 (28.7%)	1263 (27.3%)	0.03	322 (28.5%)	329 (29.2%)	0.02
Hypothyroid	150 (12.9%)	500 (10.8%)	0.07	145 (12.9%)	158 (14.0%)	0.03
Obesity	255 (21.9%)	998 (21.5%)	0.01	250 (22.2%)	268 (23.8%)	0.04
Peripheral vascular disorders	145 (12.5%)	424 (9.1%)	0.11	139 (12.3%)	166 (14.7%)	0.07
Renal failure	214 (18.4%)	588 (12.7%)	0.16	205 (18.2%)	221 (19.6%)	0.04
Mood disorder	405 (34.9%)	1448 (31.2%)	0.08	388 (34.4%)	409 (36.3%)	0.04
Current smoker	333 (28.7%)	1065 (23.0%)	0.13	318 (28.2%)	338 (30.0%)	0.04

^aOther factors not listed that were used for balancing cohorts included: month/year of COVID-19 index date, testing site, and any risk factor for severe COVID-19 occurring at a frequency of <10% (pregnancy, chronic liver disease, active chemotherapy, alcohol, blood loss anemia, coagulopathy, deficiency anemia, drug abuse, HIV/AIDS, liver disease, lymphoma, metastatic cancer, other neurological disorders, paralysis, peptic ulcer disease, psychosis, pulmonary circulation disorder, rheumatoid arthritis/collagen vascular disease, solid tumor metastasis, valvular disease, weight loss, bone marrow/organ transplant).

^bHealthcare utilization in the 3 months prior to COVID-19 index date.

^cPortal Account denotes Mayo Clinic's EHR-integrated web or mobile patient online services platform that facilitates secure messaging, appointment scheduling, bill pay, etc.

Journal Pre-proof

Table 2. Care utilization and mortality outcomes between non-engaged and engaged patients enrolled in the COVID-19 RPM program

Outcomes ^a	Non-Engaged (n=1128)	Engaged (n=1128)	OR (95% CI)	P-Value
ED Visits				
≥1 ED Visit (Unique Patients)	158 (14.0%)	171 (15.2%)	1.10 (0.87, 1.39)	0.44
>1 ED Visit (Unique Patients)	27 (2.4%)	49 (4.3%)	1.85 (1.15, 2.98)	0.01
ED Visit Converted to Inpatient Hospitalization	87 (7.7%)	99 (8.8%)	1.15 (0.85, 1.55)	0.36
Hospital Admissions				
≥1 Admission (Unique Patients)	203 (18.0%)	154 (13.7%)	0.72 (0.57, 0.90)	0.01
>1 Admission (Unique Patients)	41 (3.6%)	29 (2.6%)	0.70 (0.43, 1.13)	0.15
Prolonged Hospitalization (7 or more days)	76 (6.7%)	39 (3.5%)	0.50 (0.33, 0.74)	0.001
ICU Admissions	47 (4.2%)	26 (2.3%)	0.54 (0.33, 0.88)	0.01
Mortality (30 day)	19 (1.7%)	6 (0.5%)	0.31 (0.12, 0.78)	0.01
Outcomes			Mean Difference (95% CI)	P-Value
Average Length of Stay^b				
Mean (SD)	6.7 (6.0)	5.4 (4.7)	-1.3 (-2.4, -0.1)	0.03
Median (Range)	5 (1-30)	5 (1-30)		
Total Hospital Days^b				
Total	1660	1026		
Mean (SD)	8.2 (7.2)	6.7 (6.0)	-1.5 (-2.9, -0.1)	0.04
Median (Range)	6 (1-30)	5 (1-30)		
Total ICU Days^c				
Total	313	119		

Mean (SD)	6.7 (7.6)	4.6 (4.9)	-2.5 (-5.4, 1.2)	0.21
Median (Range)	3 (1-30)	3 (1-21)		
Overall Cost of Care				
Mean (SE)	\$3,565.97 (\$525.25)	\$2,306.33 (\$325.22)	-\$1,259.64	0.04

^aAll data are reported for events that occurred within 30 days of RPM program enrollment for outpatient diagnosis or 30 days from discharge of a hospitalized patient.

^bData reported for those patients who were hospitalized.

^cData reported for those patients who had an ICU admission.

Journal Pre-proof

Table 3. Subgroup analysis – care utilization and mortality outcomes among those with COVID-19 diagnosed while hospitalized and RPM-enrolled upon discharge to home

Outcomes ^a	Non-Engaged (n=240)	Engaged (n=254)	OR (95% CI)	P-Value
ED Visits				
≥1 ED Visit (Unique Patients)	37 (15.4%)	37 (14.6%)	0.94 (0.57, 1.53)	0.79
>1 ED Visit (Unique Patients)	10 (4.2%)	9 (3.5%)	0.84 (0.34, 2.12)	0.72
ED Visit Converted to Inpatient Hospitalization	39 (16.3%)	40 (15.8%)	0.96 (0.60, 1.56)	0.88
Hospital Admissions				
≥1 Admission (Unique Patients)	51 (21.3%)	40 (15.8%)	0.69 (0.44, 1.09)	0.12
>1 Admission (Unique Patients)	10 (4.2%)	10 (4.0%)	0.94 (0.39, 2.31)	0.90
Prolonged Hospitalization (7 or more days)	23 (9.6%)	9 (3.5%)	0.35 (0.16, 0.77)	0.01
ICU Admissions	14 (5.8%)	8 (3.2%)	0.52 (0.22, 1.28)	0.16
Mortality (30 day)	5 (2.1%)	2 (0.8%)	0.37 (0.07, 1.94)	0.24
Outcomes			Mean Difference (95% CI)	P-Value
Average Length of Stay^b				
Mean (SD)	7.5 (7.0)	4.8 (3.5)	-2.7 (-5.1, -0.3)	0.03
Median (Range)	6 (1-30)	4 (1-18)		
Total Hospital Days^b				
Total	450	262		
Mean (SD)	8.8 (7.8)	6.6 (6.4)	-2.3 (-5.3, 0.8)	0.14
Median (Range)	7 (1-30)	5 (1-28)		
Total ICU Days^c				

Total	68	27		
Mean (SD)	4.9 (5.7)	3.4 (3.3)	-1.5 (-6.1, 3.1)	0.51
Median (Range)	3 (1-19)	2 (1-10)		

^aAll data are reported for events that occurred within 30 days of RPM program enrollment for outpatient diagnosis or 30 days from discharge of a hospitalized patient.

^bData reported for those patients who had a hospital admission.

^cData reported for those patients who had an ICU admission.

Journal Pre-proof

Table 4. Subgroup analysis – care utilization and mortality outcomes among those diagnosed with COVID-19 and RPM-enrolled in the ambulatory setting

Outcomes ^a	Non-Engaged (n=888)	Engaged (n=874)	OR (95% CI)	P-Value
ED Visits				
≥1 ED Visit (Unique Patients)	121 (13.6%)	134 (15.3%)	1.15 (0.88, 1.50)	0.31
>1 ED Visit (Unique Patients)	17 (1.9%)	40 (4.6%)	2.46 (1.38, 4.37)	0.002
ED Visit Converted to Inpatient Hospitalization	48 (5.4%)	59 (6.8%)	1.27 (0.86, 1.88)	0.24
Hospital Admissions				
≥1 Admission (Unique Patients)	152 (17.1%)	114 (13.0%)	0.73 (0.56, 0.94)	0.02
>1 Admission (Unique Patients)	31 (3.5%)	19 (2.2%)	0.61 (0.34, 1.10)	0.10
Prolonged Hospitalization (7 or more days)	53 (6.0%)	30 (3.4%)	0.56 (0.35, 0.89)	0.01
ICU Admissions	33 (3.7%)	18 (2.1%)	0.54 (0.30, 0.98)	0.04
Mortality (30 day)	14 (1.6%)	4 (0.5%)	0.29 (0.09, 0.88)	0.03
Outcomes			Mean Difference (95% CI)	P-Value
Average Length of Stay^b				
Mean (SD)	6.4 (5.6)	5.6 (5.0)	-0.8 (-2.1, 0.5)	0.23
Median (Range)	5 (1-30)	5 (1-30)		
Total Hospital Days^b				
Total	1210	764		
Mean (SD)	8.0 (7.0)	6.7 (5.8)	-1.3 (-2.9, 0.3)	0.12
Median (Range)	5 (1-30)	5 (1-30)		
Total ICU Days^c				
Total	245	92		

Mean (SD)	7.4 (8.2)	5.1 (5.4)	-2.3 (-6.6, 2.0)	0.29
Median (Range)	4 (1-30)	3 (1-21)		

^aAll data are reported for events that occurred within 30 days of RPM program enrollment for outpatient diagnosis or 30 days from discharge of a hospitalized patient.

^bData reported for those patients who had a hospital admission.

^cData reported for those patients who had an ICU admission.

Journal Pre-proof

